Page last updated: 2024-10-22

ethacridine and Leukemia, Myeloid, Acute

ethacridine has been researched along with Leukemia, Myeloid, Acute in 2 studies

Ethacridine: A topically applied anti-infective agent.

Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rotin, LE2
Gronda, M2
MacLean, N2
Hurren, R2
Wang, X2
Lin, FH2
Wrana, J1
Datti, A2
Barber, DL1
Minden, MD2
Slassi, M1
Schimmer, AD2
Aman, A1
Wrana, JL1
Al-Awar, R1

Other Studies

2 other studies available for ethacridine and Leukemia, Myeloid, Acute

ArticleYear
Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism.
    Oncotarget, 2016, Jan-19, Volume: 7, Issue:3

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; Cell Line, Tumor; Drug Synergism;

2016
Erlotinib synergizes with the poly(ADP-ribose) glycohydrolase inhibitor ethacridine in acute myeloid leukemia cells.
    Haematologica, 2016, Volume: 101, Issue:11

    Topics: Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Ethacridine; Glycoside Hydrolases; Humans

2016